DSpace Repository

Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study

Show simple item record

dc.contributor.author Blümel, Juan E.
dc.contributor.author Arteaga, Eugenio
dc.contributor.author Aedo, Sócrates
dc.contributor.author Arriola-Montenegro, José
dc.contributor.author López, Marcela
dc.contributor.author Martino, Mabel
dc.contributor.author Miranda, Carlos
dc.contributor.author Miranda, Octavio
dc.contributor.author Mostajo, Desireé
dc.contributor.author Ñañez, Mónica
dc.contributor.author Ojeda, Eliana
dc.contributor.author Pilnik, Susana
dc.contributor.author Rojas, José
dc.contributor.author Salinas, Carlos
dc.contributor.author Sosa, Lida
dc.contributor.author Spritzer, Poli M.
dc.contributor.author Tserotas, Konstantinos
dc.contributor.author Vallejo, María S.
dc.contributor.author Belardo, Alejandra
dc.contributor.author Fighera, Tayane M.
dc.contributor.author Chedraui, Peter
dc.date.accessioned 2020-07-14T00:00:57Z
dc.date.available 2020-07-14T00:00:57Z
dc.date.issued 2020
dc.identifier.uri https://hdl.handle.net/20.500.12866/8236
dc.description.abstract Metformin may decrease cell senescence, including bone; hence we aimed at evaluating the association between metformin use and osteoporosis. This was a cross-sectional study carried out in 1259 Latin American adult women aged 40 or more who were not on anti-osteoporotic drugs, were on metformin and had a bone densitometry performed. Of the whole sample, 40.3% reported being on metformin (at least 1 year), 30.2% had type 2 diabetes mellitus and 22.6% had osteoporosis. Median (interquartile range) body mass index (BMI) for the whole cohort was 27.7 (4.6) kg/m2 and 30.2% had type 2 diabetes mellitus. Current use of hormone therapy, calcium, and vitamin D corresponded respectively to 10.7%, 47.7%, and 43.1% of all surveyed women. A logistic regression model was used to analyze the association of osteoporosis with various covariates incorporated into the model such as age (OR: 1.07, 95% CI: 1.05–1.09), BMI (OR: 0.92, 95% CI: 0.89–0.96) and metformin use (OR: 0.44, 95% CI: 0.32–0.59). Metformin use, regardless of the presence of type 2 diabetes or obesity, was associated with a lower risk of osteoporosis in adult women. We propose that one explanation for this observation could be the effect of the drug over cellular senescence. en_US
dc.language.iso eng
dc.publisher Taylor and Francis
dc.relation.ispartofseries Gynecological Endocrinology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject aging en_US
dc.subject Metformin en_US
dc.subject osteoporosis en_US
dc.subject senescence en_US
dc.title Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1080/09513590.2020.1718092
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.18
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.02
dc.relation.issn 1473-0766


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics